| Identification | Back Directory | [Name]
Lintuzumab | [CAS]
166089-32-3 | [Synonyms]
Hum 195
Lintuzumab
Lintuzumab [inn]
Immunoglobulin G1, anti-(human cd33 (antigen)) (human-mouse monoclonal hum195 gamma1-chain), disulfide with human-mouse monoclonal hum195 kappa-chain, dimer |
| Hazard Information | Back Directory | [Uses]
Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonal antibody. Lintuzumab reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells. Lintuzumab promotes tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities against MDR and MDR+ AML cell lines and primary AML patient samples. Lintuzumab enhances survival and reduces tumor burden in mice[1]. | [IC 50]
RDC Antibody | [References]
[1] Lintuzumab |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
| Company Name: |
Leancare Ltd.
|
| Tel: |
+33 962096793 |
| Website: |
www.leancare.co.uk |
|